MannKind Q2 2026 revenue $109.4M (+43% YoY); Afrezza pediatric and Furoscix ReadyFlow approved

MANNKIND CORP

Q2 total revenue $109.4M, up 43% YoY; Furoscix contributed $22.2M in net sales.
Afrezza net sales $17.0M (-7% YoY); pediatric indication approved May 29, early launch momentum.
Furoscix ReadyFlow autoinjector approved July 23; commercial launch expected late August.
Positive Phase 1b data for nintedanib DPI (MNKD-201) in IPF; global Phase 2 enrolling.
Closed $50M private placement to fund $45M CVR payment from Furoscix ReadyFlow approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.